Af­ter an R&D odyssey filled with set­backs, Clo­vis wins an FDA OK for ru­ca­parib

Clo­vis On­col­o­gy $CLVS won some re­demp­tion to­day, gain­ing an ac­cel­er­at­ed ap­proval for its first drug and set­ting it on a short path to com­mer­cial­iza­tion.

The FDA has ap­proved its PARP in­hibitor ru­ca­parib, to be sold as Rubra­ca, to treat ovar­i­an can­cer cas­es with BR­CA mu­ta­tions. The drug is en­ter­ing a mar­ket that will be sliced and diced by a va­ri­ety of com­peti­tors. The Foun­da­tion­Fo­cus CDxBR­CA com­pan­ion di­ag­nos­tic was al­so OK’d for use with Rubra­ca.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.